Apricus Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

APRI 1.85 +0.17 (10.12%)
price chart
Top Growth Pick: Apricus Biosciences, Inc (NASDAQ:APRI)
Apricus Biosciences, Inc (NASDAQ:APRI) has received a top Growth Style score from Zack's Research. The growth score is based on company financials as well as the company's prospects for future growth.
Apricus Biosciences Is Executing Its Strategic Plans (APRI)
For the past few years, Apricus Biosciences, Inc. (NASDAQ:APRI) has attempted to turn its trajectory around and focus on a long-term strategy.
Apricus Biosciences Announces Last Patient Enrolled in RayVa Phase 2a ...
Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has enrolled the last patient in its RayVa™ Phase 2a proof-of-concept study.
Apricus Biosciences Announces Last Patient Enrolled in RayVa(TM) Phase 2a ...  MarketWatch
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for ...
SAN DIEGO, May 28, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch of Vitaros´┐Ż in France by Laboratoires ...
Apricus Biosciences And Vitaros: Update On The Launch (APRI)
It's been almost six months since Vitaros was first launched by Apricus Biosciences (NASDAQ:APRI) in the UK, with follow-up launches in Germany, Sweden and Belgium.
Related articles »  
Apricus Biosciences Enrolls First Patients in Phase 2b Clinical Trial for ...
SAN DIEGO, June 1, 2015 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has begun enrolling patients in a Phase 2b ...
Why Apricus With Vitaros Intrigues Investors (APRI)
2015 represents a turning point for Apricus Biosciences (NASDAQ:APRI). Vitaros, the lead product for the treatment of ED, is a topically-applied cream formulation of alprostadil, a vasodilator and NexACT, which directly increases blood flow to the ...
RayVa Patent Award Sends Apricus Biosciences Inc (APRI) Stock Trading Up
Apricus Biosciences Inc. (NASDAQ:APRI) is trading up by around 15.58% as of 11:14 AM EST. The buying spree on the stock followed the announcement from the United States Patent and Trademark Office (USPTO) on Tuesday, awarding the patent to ...
Apricus Biosciences Announces Issuance of U.S. Patent for RayVa(TM)  GlobeNewswire (press release)
Apricus Biosciences And Vivus: A Potential Golden Marriage
In case Apricus gets directly involved in the commercialization of its products in the US, the company will face a full transformation from a development company to a commercial one.
Apricus Biosciences: A Screaming Buy Or A Falling Knife?
Apricus Biosciences, Inc. (NASDAQ:APRI) recently began their launch of Vitaros, a topical treatment for Erectile Dysfunction (NYSE:ED), with availability in the UK, Sweden, and now Germany.